No profile data available.
Lucid Diagnostics Inc. (LUCD) is a healthcare company in the medical testing laboratories industry, based in New York, United States, with about 82 full-time employees.
It reported revenue of $4.71 million for fiscal year 2025, up 8.2% from fiscal year 2024, and net income of -$70.57 million. Its market capitalization was $121.83 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Lucid Diagnostics reported $4.71 million in revenue for fiscal year 2025, up 8.2% from $4.35 million in fiscal year 2024.
$121.83 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medical testing laboratories) include Fulgent Genetics, Inc. (FLGT), Biodesix, Inc. (BDSX), Prenetics Global Limited (PRE), Precipio, Inc. (PRPO).